← Oncology Approval Tracker

FDA DECISION ·

Tibsovo

ivosidenib · Servier Pharmaceuticals

FDA approvalNew or expanded indicationMyelodysplastic syndromes
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory myelodysplastic syndromes and a susceptible IDH1 mutation on an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

This use extended IDH1-targeted therapy to a molecularly selected MDS population.

What research teams should watch

Verify the IDH1 result and prior therapy, and plan differentiation syndrome recognition and escalation.

PRIMARY RECORDS

Sources